List of Excipients in Branded Drug LORATADINE

« Back to Dashboard

Generic Drugs Containing LORATADINE

Company	Ingredient	NDC	Excipient
Walgreen Company	loratadine	0363-0522	LACTOSE MONOHYDRATE
Walgreen Company	loratadine	0363-0522	MAGNESIUM STEARATE
Walgreen Company	loratadine	0363-0522	STARCH, CORN

What are the Most Frequently-Used Excipients in LORATADINE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
29	ANHYDROUS CITRIC ACID
5	ASCORBIC ACID

Loratadine Excipient Strategy, Formulation Patents, Generic Competition, and Commercial Opportunities

Last updated: October 10, 2026

Loratadine is a mature, low-cost second-generation antihistamine with no meaningful active-ingredient patent barrier in the United States. Commercial opportunities are concentrated in formulation performance, differentiated delivery systems, pediatric products, taste masking, combination products, global markets, and manufacturing efficiency. The strongest excipient strategies address loratadine’s poor aqueous solubility, low dose, bitter taste, and demand for rapid, convenient administration.

What is the current FDA and Orange Book status of loratadine?

Loratadine is an FDA-approved antihistamine for temporary relief of allergic rhinitis and chronic urticaria symptoms. It is marketed in prescription and over-the-counter products, including tablets, chewable tablets, orally disintegrating tablets, capsules, and oral solutions.

The original Claritin product transitioned from prescription to OTC status in the United States in 2002. Loratadine products are now widely supplied by generic manufacturers, private-label retailers, and consumer-health companies.

Regulatory and commercial attribute	Current position
Active ingredient	Loratadine
Therapeutic class	Second-generation H1 antihistamine
Common adult dose	10 mg once daily
Pediatric dosing	Age- and formulation-dependent
FDA status	Approved and widely marketed
OTC status	Established in the United States
Reference brand	Claritin
Biosimilar pathway	Not applicable; loratadine is a small molecule
Active-ingredient patent barrier	Expired
Generic availability	Broad
Orange Book relevance	Historical patent and exclusivity significance; limited current protection for the active ingredient
Primary competitive factors	Price, retailer access, dosage form, taste, packaging, and supply reliability

FDA OTC monograph M012 covers antihistamine drug products, including loratadine, subject to applicable conditions for labeling, dosage, and use.[1] Current commercial products must also comply with FDA requirements for inactive ingredients, manufacturing controls, stability, labeling, and, where applicable, OTC monograph conditions.

When did loratadine lose patent exclusivity?

Loratadine’s core U.S. patent protection expired years ago. The original Claritin exclusivity period ended after generic manufacturers obtained regulatory approval and launched competing products in the early 2000s.

The commercially important patent history included:

Patent category	Commercial status
Loratadine active-ingredient patent	Expired
Core composition-of-matter protection	Expired
Original Claritin product protection	Expired or commercially irrelevant
Pediatric exclusivity	Expired
Brand formulation protection	Expired, narrow, or not commercially blocking
Current generic entry barrier	None of practical significance for standard 10 mg products

Historical patent term calculations depended on filing dates, grant dates, patent-term rules, patent-term adjustments, and regulatory extensions. Loratadine is now a mature generic active ingredient, so the principal business question is not whether the active ingredient remains protected. It is whether a new product can obtain meaningful differentiation without relying on expired Claritin technology.

What excipients are used in loratadine formulations?

Loratadine is practically insoluble in water. The molecule’s low aqueous solubility creates formulation challenges despite the relatively small 10 mg dose. Commercial products commonly use excipients for dilution, powder flow, compaction, disintegration, suspension, taste masking, sweetness, and stability.

Typical excipient groups include:

Formulation function	Common excipient options
Diluent	Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate
Glidant	Colloidal silicon dioxide
Sweetener	Sucrose, sorbitol, sucralose, aspartame, acesulfame potassium
Flavor	Fruit flavors, mint flavors, vanilla or masking systems
Suspending agent	Xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose systems
Solubilizer or wetting agent	Polysorbates, poloxamers, surfactant systems
Film former	Hypromellose, polyvinyl alcohol, polyethylene glycol-containing coatings
Preservative for liquids	Sodium benzoate, potassium sorbate, or other permitted systems
pH modifier	Citric acid, sodium citrate, phosphate buffers

The exact formulation must be taken from the approved product label or product-specific inactive-ingredient disclosure. Excipients cannot be inferred solely from the dosage form because different manufacturers use different manufacturing platforms.

Which excipient strategies improve loratadine solubility and dissolution?

The most commercially relevant technical problem is increasing dissolution without creating unacceptable stability, taste, or manufacturing risk.

Amorphous solid dispersions

Loratadine can be formulated with polymers such as hypromellose, hydroxypropyl cellulose, or polyvinylpyrrolidone to increase apparent solubility and maintain the drug in a higher-energy amorphous state.

The main risks are recrystallization, moisture sensitivity, processing complexity, and the need for strong analytical control. A solid dispersion has commercial value only if it produces a measurable benefit in dissolution, onset, dose uniformity, or dosage-form size.

Particle-size reduction

Micronization or controlled particle engineering can increase surface area and improve dissolution. The approach is generally simpler than a solid dispersion but can create powder-flow, electrostatic, segregation, and content-uniformity problems.

For a 10 mg tablet, particle-size reduction can be attractive where the formulation must remain small or where the developer wants to avoid a complex polymer system.

Wetting and surfactant systems

Surfactants and wetting agents can improve contact between loratadine particles and gastrointestinal fluids. The strategy is useful in liquid, orally disintegrating, and fast-dissolving products but requires compatibility and taste testing.

Excess surfactant can cause foaming, gastrointestinal tolerability issues, tablet defects, or an unpleasant mouthfeel.

Complexation and lipid-based systems

Cyclodextrins, lipid carriers, and self-emulsifying systems may increase apparent solubility. These approaches are technically differentiated but face higher excipient cost, scale-up requirements, and regulatory scrutiny.

For a mature OTC product, the commercial case must justify the added cost through a clear claim such as faster dissolution, smaller dose form, improved pediatric administration, or improved performance under specific conditions.

What formulations are commercially attractive for loratadine?

Orally disintegrating tablets

Orally disintegrating tablets remain one of the strongest formulation opportunities. They can be taken without water and are suitable for travel, seasonal allergy use, and consumers who have difficulty swallowing conventional tablets.

Key excipient requirements include:

• A highly porous tablet structure
• Rapid wetting and disintegration
• Low friability
• Efficient taste masking
• Acceptable mouthfeel
• Moisture-protective packaging

Mannitol is frequently attractive because it can provide a cooling sensation and a relatively clean mouthfeel. Crospovidone, croscarmellose sodium, and specialized co-processed excipients can support rapid disintegration.

The major commercial risks are loratadine bitterness, tablet fragility, and moisture uptake. Aluminum-aluminum blister packaging or high-barrier unit-dose packaging can be more important than the tablet composition itself.

Chewable tablets

Chewable loratadine products target pediatric and convenience segments. Taste masking is the central development issue. Sweeteners alone may not adequately suppress the drug’s bitter profile, particularly as the tablet dissolves in the mouth.

Possible approaches include:

• Polymer film coating of drug particles
• Ion-exchange resin complexes
• Lipid or wax barriers
• pH-dependent coating systems
• Flavor layering
• Combination sweetener systems

Taste-masking technologies can support formulation-specific patent claims if they produce a reproducible, non-obvious performance benefit. The commercial risk is that a complex taste-masking process may cost more than the market will support.

Oral solutions and syrups

Liquid loratadine products address young children and patients who cannot swallow tablets. Because loratadine has low water solubility, developers must distinguish between a true solution, a suspension, and a solubilized system.

Important development variables include:

• Solubilizer concentration
• Preservative efficacy
• pH
• Viscosity
• Sedimentation
• Redispersibility
• Flavor stability
• Container compatibility
• Dosing-device accuracy

A suspension may be less technically elegant than a solubilized liquid but can be more robust and less expensive. A clear solution has stronger consumer appeal but usually requires more extensive excipient and stability optimization.

Standard immediate-release tablets

Standard tablets remain the lowest-cost and highest-volume format. The main opportunity is operational rather than technological: low-cost excipients, high-speed compression, low reject rates, reliable content uniformity, and packaging efficiency.

A conventional formulation may use lactose or microcrystalline cellulose as diluent, a superdisintegrant, magnesium stearate, and a film coat. The formulation is difficult to protect broadly because many competing products use similar excipient classes.

What formulation patents could protect a loratadine product?

A new loratadine product cannot rely on broad claims covering the active ingredient. Potentially protectable subject matter includes:

1. A defined particle-size distribution.
2. An amorphous loratadine composition with specified crystallinity limits.
3. A solid dispersion with a selected polymer ratio.
4. A taste-masked loratadine particle or granule.
5. A rapidly disintegrating tablet with specified dissolution performance.
6. A low-moisture orally disintegrating formulation.
7. A stable pediatric liquid with defined pH and preservative levels.
8. A multiparticulate dosage form with controlled release or delayed release.
9. A manufacturing process that improves content uniformity or reduces degradation.
10. A specific combination of loratadine with another active ingredient.

Patent strength depends on whether the claims cover a commercial product rather than merely a laboratory composition. Claims limited to routine excipient substitutions are vulnerable to obviousness challenges. Claims tied to unexpected dissolution, stability, taste, or manufacturability results are stronger.

Are method-of-use patents available for loratadine?

Method-of-use opportunities are limited because loratadine has long-established indications. Broad claims for allergic rhinitis or urticaria are unlikely to provide meaningful exclusivity.

Potentially differentiated uses could involve:

• A defined patient subgroup
• A specific dosing schedule
• A new administration setting
• A new combination treatment
• A pediatric population with a distinct formulation
• A symptom cluster supported by clinical evidence

Regulatory and patent value would depend on whether the proposed use has a credible clinical benefit and whether the labeling can support the claimed indication. A method-of-use patent would not necessarily prevent generic manufacturers from selling standard loratadine for established indications.

What Paragraph IV challenges and litigation affect loratadine?

Loratadine experienced historical generic competition and patent disputes during the transition from Claritin prescription sales to OTC marketing. Those disputes are no longer a material barrier to ordinary generic loratadine entry.

Current commercial litigation risk is more likely to involve:

• Trade dress
• Trademark use
• OTC labeling
• Advertising claims
• Product liability
• Retailer private-label contracts
• Formulation-specific patents
• Combination-product patents
• Manufacturing process disputes

A Paragraph IV strategy would have limited value against expired core loratadine patents. It could become relevant only if a new branded product obtained a valid patent covering a specific formulation, dosage regimen, or combination.

Which companies compete in loratadine?

Competition exists across four groups:

Competitor group	Examples of commercial strategy
Branded consumer health	Claritin and retailer-recognized equivalents
Generic pharmaceutical companies	Low-cost tablets, capsules, liquids, and chewables
Retail private labels	Price-led loratadine products sold through pharmacy and supermarket chains
Combination-product manufacturers	Loratadine with decongestant actives such as pseudoephedrine

The strongest competitive advantages are distribution, retailer placement, packaging, supply continuity, and consumer recognition. A technically improved formulation must also secure a clear commercial position because standard loratadine is inexpensive and familiar.

What is the biosimilar risk for loratadine?

There is no biosimilar risk. Loratadine is a chemically synthesized small-molecule drug, not a biologic. Competitive entry occurs through the generic drug pathway, abbreviated new drug applications, OTC monograph compliance, or other applicable national regulatory routes.

The relevant substitution risk is generic erosion, not biosimilar interchangeability. In the United States, pharmacists and consumers can access numerous loratadine alternatives, creating substantial price pressure on undifferentiated products.

How strong is the loratadine patent estate?

The patent estate for unmodified loratadine is weak from a current commercial-exclusivity perspective.

Estate component	Strength
Core active ingredient	Very weak; expired
Standard 10 mg tablet	Weak
Conventional liquid	Weak unless technically differentiated
Orally disintegrating tablet	Moderate only if claims are formulation-specific
Taste-masked pediatric product	Moderate if supported by strong data
Amorphous or solid-dispersion product	Moderate, with freedom-to-operate risk
Combination product	Variable and dependent on the other active
Manufacturing process	Potentially moderate but difficult to enforce
Trademark and trade dress	Commercially relevant but not patent exclusivity

A new entrant should conduct a freedom-to-operate review across formulation patents, excipient technology licenses, packaging claims, trademarks, and combination-product patents. Active patent status must be checked by jurisdiction and as of the proposed launch date.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are execution-related:

• Achieving uniform distribution of a low-dose active
• Controlling loratadine particle size
• Preventing segregation during blending
• Managing powder flow
• Limiting moisture exposure
• Maintaining tablet hardness without slowing dissolution
• Achieving acceptable taste in chewable and ODT products
• Preventing sedimentation in liquid products
• Producing stable packaging at low cost

The most defensible IP may reside in a process that solves one of these problems at commercial scale. Examples include a narrow granulation window, a controlled spray-drying process, a specialized taste-masking coating, or a packaging system that maintains ODT performance under high humidity.

What commercial opportunities exist for loratadine?

The strongest opportunities are:

Pediatric and family products

Pediatric liquids, chewables, and unit-dose sachets can command more value than plain adult tablets if taste, dosing accuracy, and convenience are superior.

Premium orally disintegrating products

A fast-disintegrating, pleasant-tasting product can compete on convenience rather than price. Packaging and stability are central to the proposition.

Combination products

Loratadine-pseudoephedrine products address congestion as well as allergy symptoms. They have higher regulatory and abuse-control complexity, particularly because pseudoephedrine is subject to restrictions in the United States.

Global markets

Demand exists in countries where OTC allergy treatment is expanding or where local manufacturers seek reliable active pharmaceutical ingredient supply. Geographic strategy should account for local monographs, permitted excipients, labeling rules, pediatric requirements, and patent status.

Contract development and manufacturing

Specialized manufacturers can offer taste masking, ODT platforms, liquid formulation, particle engineering, and private-label development. The value proposition is strongest where the customer lacks internal formulation or scale-up capability.

Ingredient and excipient supply

Suppliers can target co-processed direct-compression excipients, taste-masking systems, moisture-barrier packaging, and solubilization technologies. These products may generate recurring revenue across multiple antihistamine and OTC platforms.

How does loratadine compare with cetirizine and fexofenadine?

Attribute	Loratadine	Cetirizine	Fexofenadine
Drug class	Second-generation antihistamine	Second-generation antihistamine	Second-generation antihistamine
Typical adult dose	10 mg once daily	5 or 10 mg once daily	Dose varies by product
Core patent status	Expired	Expired	Expired
Generic competition	High	High	High
Formulation opportunity	ODT, chewable, liquid, combinations	ODT, chewable, liquid	Tablets, liquids, high-dose formats
Main excipient challenge	Solubility and taste	Taste and patient acceptance	Dose size and formulation performance
Commercial differentiation	Convenience and pediatric delivery	Rapid consumer substitution and price	Brand recognition and dose positioning

Loratadine’s low dose supports small tablets and flexible pediatric formats. Cetirizine may compete strongly on perceived efficacy but can be associated with consumer concerns about drowsiness. Fexofenadine often requires larger active-ingredient loads, creating different tablet-size and manufacturing considerations.

Key Takeaways

• Loratadine’s core patent and regulatory exclusivity have expired.
• The United States has broad generic and OTC competition.
• Excipient strategy should focus on dissolution, taste masking, rapid disintegration, liquid stability, and manufacturing efficiency.
• Orally disintegrating, chewable, pediatric liquid, and combination products offer the clearest commercial opportunities.
• Standard immediate-release tablets are primarily price and supply-chain businesses.
• Formulation patents can be valuable when tied to unexpected performance and commercially relevant manufacturing advantages.
• Biosimilar risk does not apply because loratadine is a small-molecule drug.
• Paragraph IV litigation is mainly historical for ordinary loratadine products.
• The strongest current barriers are execution, formulation know-how, packaging, distribution, and retailer access.

FAQs About Loratadine Excipient and Commercial Strategy

Can lactose be used in loratadine tablets?

Yes. Lactose is a common tablet diluent, but the final formulation must address compatibility, flow, compression, moisture, and patient-specific labeling requirements.

What is the best excipient for loratadine taste masking?

No single excipient is universally best. Polymer coatings, ion-exchange resins, lipid barriers, and flavor-sweetener systems should be selected based on bitterness intensity, dosage form, release target, and manufacturing cost.

Is loratadine suitable for an orally disintegrating tablet?

Yes. Its low dose makes loratadine suitable for ODT development, although taste masking, tablet strength, moisture protection, and rapid disintegration require optimization.

Can a new loratadine product receive patent protection?

Yes, but protection would generally need to cover a novel formulation, delivery system, process, combination, or clinically differentiated use rather than loratadine itself.

Does loratadine require a prescription in the United States?

No. Loratadine is widely available OTC in the United States, although regulatory requirements differ by dosage form, combination, labeling, and product-specific approval pathway.

References

1. U.S. Food and Drug Administration. (2022). Antihistamine drug products for over-the-counter human use: Final monograph, 21 C.F.R. § 341 and applicable OTC monograph provisions. FDA.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. National Library of Medicine. (n.d.). DailyMed: Loratadine drug labels. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, loratadine monograph. USP Convention.

5. U.S. Food and Drug Administration. (2002). FDA approves switch of Claritin from prescription to over-the-counter status. FDA.